OPDUALAG 240 mg/80 mg, concentrate for solution for infusion bottle, 20 ml
Active ingredients: Nivolumab, RÉLATLIMAB
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Concentrate for solution for infusionbottle, 20 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OPDUALAG 240 mg/80 mg, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 20 ml
- Marketing authorisation holder
- BRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 Feb 2025
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
62235699CIP75509204CIP133400955092049Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| NIVOLUMABsolution | 12 mg · 1 mL de solution | SA |
| RÉLATLIMABsolution | 4 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.